revance®
REMARKABLE SCIENCE. ENDURING PERFORMANCE.™

INVESTOR FACT SHEET

Issued November 9, 2018

KEY HIGHLIGHTS

October 11, 2018
Revance appoints Tobin C. Schilke as Chief Financial Officer

June 21, 2018
Revance Doses First Patient in ASPEN Phase 3 Clinical Program of RT002 Injectable for the Treatment of Cervical Dystonia

COMPANY BASICS

Headquarters
Revance Therapeutics, Inc.
7555 Gateway Boulevard
P.O. Box 303
Newark, California 94560-0303
Phone:(510)742-3400

Employees: 149*
Website: www.revance.com

Stock Symbol: RVNC
Stock Exchange: NASDAQ
Market Cap: ~$900 million*

Key Contacts
Investor Relations:
Jeanie Herbert
714-325-3584
jherbert@revance.com

Burns McClellan
Ami Bavishi
212-213-0006
abavishi@burnsmc.com

Trade Media:
Nadine Tosk
(847) 920-9858
nadinepr@gmail.com

General Media:
TOGORUN
Mariann Caprino
(917) 242-1087
mcaprino@togorun.com

Transfer Agent
Computershare
+1 (877) 373 6374 (US, Canada, Puerto Rico)
+1 (781) 575 3120 (non-US)
For requests by email:
web.queries@computershare.com

WWW.REVANCE.COM

First True Innovation in Neuromodulators in 30 Years

ABOUT REVANCE THERAPEUTICS, INC.

Revance, a Silicon Valley-based biotechnology company, is committed to the advancement of remarkable science. The company is developing a portfolio of products for aesthetic medicine and therapeutic indications in neuroscience.

Revance's initial focus is on developing daxibotulinumtoxinA, the company's highly purified botulinum toxin Type A, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles, muscle movement disorders and chronic migraine. Current sales of neuromodulators are estimated to be $4 billion globally and are expected to grow to $7 billion by 2024.**

The company's lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in Phase 3 clinical development and has the potential to be the first long-acting neuromodulator and the first innovation in neuromodulation in 30 years. Revance is studying RT002 for the treatment of glabellar lines, cervical dystonia, plantar fasciitis, upper limb spasticity and chronic migraine. The company also is developing a topically applied neuromodulator for aesthetic and therapeutic indications, DaxibotulinumtoxinA Topical, and has a collaboration and license agreement with Mylan to develop and commercialize a biosimilar to BOTOX®.

PROPRIETARY PEPTIDE TECHNOLOGY

Revance used its unique proprietary peptide technology to formulate RT002. The noncovalent bond formed between the peptide and the botulinum toxin may enable longer residence time of botulinum toxin Type A, which could explain RT002's long duration of effect. The process binds a highly purified botulinum toxin Type A with a unique proprietary stabilizing excipient peptide. Other botulinum toxin products in the U.S. use human serum albumin (HSA) and other animal-sourced ingredients to stabilize their product, which carry the risk of transmission of pathogens.

ADVANCING NEUROMODULATOR PIPELINE

DaxibotulinumtoxinA is a "Pipeline within a Product"



*As of September 30, 2018
**Source: Global Industry Analysts, Inc. Botulinum Toxin –A Global Strategic Business Report, Jan 2018

REMARKABLE SCIENCE. ENDURING PERFORMANCE.

REVANCE'S CLINICAL PROGRAMS

AESTHETICS

Revance is focusing on the largest segment within facial aesthetics, glabellar (frown) lines, which represents an estimated $1 billion global opportunity.



Neuromodulators work by inhibiting the muscles that make the movements that cause lines to appear on the face. When injected in very small amounts directly into the underlying muscle, the neuromodulator causes the muscle to relax so that the overlying skin is smoothed out, reducing the appearance of wrinkles. Currently marketed neuromodulators have shown duration of effect of approximately 3-4 months. In Revance's SAKURA 1 and SAKURA 2 Phase 3 pivotal trials, DaxibotulinumtoxinA for Injection (RT002) achieved a 6-month duration of effect. The company plans to complete the SAKURA 3 open-label, long-term safety study in the fourth quarter of 2018, and pending FDA approval, launch RT002 to treat frown lines in the U.S. in 2020.

THERAPEUTICS

Revance plans to build a significant therapeutics portfolio, primarily focused in neuroscience indictions.

Cervical dystonia is a very painful and debilitating neurologic disorder affecting the neck and shoulder muscles. Treatment for cervical dystonia involves regular neurological intervention. The most commonly prescribed treatment for cervical dystonia is botulinum toxin Type A, which can reduce the signs and symptoms of the affliction. In May 2017, Revance released positive 24-week results from its Phase 2 dose-escalating trial using RT002 injectable for the treatment of cervical dystonia and was granted Orphan Drug Designation by the FDA in December 2017. In June of 2018, the company initiated the ASPEN Phase 3 study for the treatment of cervical dystonia.



Plantar fasciitis, the most common cause of heel pain, is triggered by inflammation of the connective tissue in the arch of the foot. In April, the company reported 16-week results from a Phase 2a trial using RT002 injectable to reduce the signs and symptoms of plantar fasciitis. A 58% reduction in pain was observed in patients treated with RT002, although the results were not statistically significant as compared to placebo. The company plans to initiate a second Phase 2 trial in the fourth quarter of 2018.

Patients with **upper limb spasticity** experience spasms and tightness of muscles caused by stroke, multiple schlerosis or spinal injuries. Revance plans to leverage its experience in cervical dystonia to pursue an accelerated development path for RT002 as a long-acting treatment. The company plans to initiate Phase 2 studies in adult upper limb spasticity in the fourth quarter of 2018.



Between three and four million Americans experience **chronic migraine**, which is characterized by at least 15 headache days per month. Current treatment with a short-acting neuromodulator requires 31 injections administered every 12 weeks. Revance is researching the potential use of RT002 for chronic migraine, with a goal of eventually providing a product requiring fewer injections and fewer treatments per year.

2018 FINANCIAL OUTLOOK

The company had cash and investments of $208 million at September 30, 2018. Cash burn for 2018 is expected to be in the range of $117-$137 million.

SELL-SIDE COVERAGE

FIRM	ANALYST
Cantor Fitzgerald	Louise Chen
Cowen and Company	Ken Cacciatore
Goldman Sachs	Dana Flanders
JMP Securities	Don Ellis
Mizuho	Difei Yang
Needham & Company	Serge Belanger
Piper Jaffray & Company	David Amsellem
SunTrust Robinson Humphrey, Inc.	John T. Boris
William Blair	Tim Lugo

BOARD OF DIRECTORS

Angus C. Russell
Chairman of the Board

Dan Browne
Co-Founder, President & CEO

Robert Byrnes
Experienced Medical Device & Biotechnology Executive

Mark Foley
RWI Ventures

Phyllis Gardner, M.D.
Professor of Medicine, Stanford University

Julian Gangolli
GW Pharmaceuticals Inc.

Philip Vickers, Ph.D.
Northern Biologics, Inc.

EXECUTIVE MANAGEMENT TEAM

Dan Browne
Co-Founder, President & CEO

Tobin C. Schilke
Chief Financial Officer

Abhay Joshi, Ph.D.
Chief Operating Officer

Caryn McDowell
SVP, General Counsel & Corporate Secretary

Justin Ford
VP, Human Resources and Head of People

FORWARD-LOOKING STATEMENTS

This Investor Fact Sheet contains forward-looking statements, including those relating to the development of our aesthetic and therapeutic product candidates and related clinical activities; the size and growth potential of neuromodulator sales; the attributes and potential benefits of our peptide technology; our 2018 financial outlook, and other risks. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our expectations. These risks and uncertainties are risks described in the "Risk Factors" section of the Form 10Q filed November 2, 2018. These forward-looking statements speak only as of the date hereof. Revance disclaims any obligation to update these forward-looking statements.